Limits...
Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.

Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S - Cancer Sci. (2014)

Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Show MeSH

Related in: MedlinePlus

Increased frequencies of Th17 cells and reduced frequencies of Th1 cells predict poor survival in acute myeloid leukemia (AML) patients. Kaplan–Meier curves for overall survival were assessed in combination with frequencies of Th17 cells (a), frequencies of Th1 cells (b), or frequencies of Th1 together with Th17 cells (c), in bone marrow (BM) microenvironment of 98 AML patients. (d) The frequencies of Th17 cells decreased in BM when patients achieved complete remission (CR).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317867&req=5

fig06: Increased frequencies of Th17 cells and reduced frequencies of Th1 cells predict poor survival in acute myeloid leukemia (AML) patients. Kaplan–Meier curves for overall survival were assessed in combination with frequencies of Th17 cells (a), frequencies of Th1 cells (b), or frequencies of Th1 together with Th17 cells (c), in bone marrow (BM) microenvironment of 98 AML patients. (d) The frequencies of Th17 cells decreased in BM when patients achieved complete remission (CR).

Mentions: Interleukin-17A secreted by Th17 cells promotes the proliferation of AML cells and inhibits the differentiation of Th1 cells in vitro as well as elevated Th17 cell frequencies are present in BM, which suggest that Th17 cells may contribute to tumor immune escape in AML patients. We analyzed the impact of Th17 cell frequency and Th1 cell frequency in BM on patient survival. Regardless of the treatments each patient received, the patients were classified into two groups based on the median frequencies of Th17 (3.41%) or Th1 (26.16%) cells, respectively. The median overall survival in high Th17 group was significantly shorter than those in low Th17 group (P = 0.033, Fig. 6a), which suggested that increased Th17 cell frequency might be an unfavorable prognostic marker for AML patients. We also found that increased Th1 cell frequency is a favorable prognostic marker for AML patients by comparing the median survival in the high Th1 group and the low Th1 group (P = 0.025, Fig. 6b). Furthermore, patients were divided into four groups based on both the median frequencies of Th17 and Th1 cells. Irrespective of being in the low Th17 group or high Th17 group, patients with high frequencies of Th1 cells had a better survival than patients with low frequencies of Th1 cells (Fig. 6c). Thus the best combination associated with overall survival was low Th17 and high Th1 group, whereas the worst combination was the high Th17 and low Th1 group (P < 0.01). No difference was found in the high Th17 and high Th1 group and the low Th17 and low Th1 group. These data suggest that the combination of Th17 cell frequency and Th1 cell frequency is a potential marker to judge patient prognosis.


Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.

Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S - Cancer Sci. (2014)

Increased frequencies of Th17 cells and reduced frequencies of Th1 cells predict poor survival in acute myeloid leukemia (AML) patients. Kaplan–Meier curves for overall survival were assessed in combination with frequencies of Th17 cells (a), frequencies of Th1 cells (b), or frequencies of Th1 together with Th17 cells (c), in bone marrow (BM) microenvironment of 98 AML patients. (d) The frequencies of Th17 cells decreased in BM when patients achieved complete remission (CR).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317867&req=5

fig06: Increased frequencies of Th17 cells and reduced frequencies of Th1 cells predict poor survival in acute myeloid leukemia (AML) patients. Kaplan–Meier curves for overall survival were assessed in combination with frequencies of Th17 cells (a), frequencies of Th1 cells (b), or frequencies of Th1 together with Th17 cells (c), in bone marrow (BM) microenvironment of 98 AML patients. (d) The frequencies of Th17 cells decreased in BM when patients achieved complete remission (CR).
Mentions: Interleukin-17A secreted by Th17 cells promotes the proliferation of AML cells and inhibits the differentiation of Th1 cells in vitro as well as elevated Th17 cell frequencies are present in BM, which suggest that Th17 cells may contribute to tumor immune escape in AML patients. We analyzed the impact of Th17 cell frequency and Th1 cell frequency in BM on patient survival. Regardless of the treatments each patient received, the patients were classified into two groups based on the median frequencies of Th17 (3.41%) or Th1 (26.16%) cells, respectively. The median overall survival in high Th17 group was significantly shorter than those in low Th17 group (P = 0.033, Fig. 6a), which suggested that increased Th17 cell frequency might be an unfavorable prognostic marker for AML patients. We also found that increased Th1 cell frequency is a favorable prognostic marker for AML patients by comparing the median survival in the high Th1 group and the low Th1 group (P = 0.025, Fig. 6b). Furthermore, patients were divided into four groups based on both the median frequencies of Th17 and Th1 cells. Irrespective of being in the low Th17 group or high Th17 group, patients with high frequencies of Th1 cells had a better survival than patients with low frequencies of Th1 cells (Fig. 6c). Thus the best combination associated with overall survival was low Th17 and high Th1 group, whereas the worst combination was the high Th17 and low Th1 group (P < 0.01). No difference was found in the high Th17 and high Th1 group and the low Th17 and low Th1 group. These data suggest that the combination of Th17 cell frequency and Th1 cell frequency is a potential marker to judge patient prognosis.

Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Show MeSH
Related in: MedlinePlus